STRO
SUTRO BIOPHARMA, INC.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeSutro reported early-stage clinical progress on lead asset STRO-004 with confirmed partial responses and favorable tolerability, but the disclosure of dose-limiting toxicities at the highest dose triggered a sharp 24% selloff in August. The company maintains adequate cash runway into Q2 2028 and continues pipeline execution, though a September downgrade to 'strong sell' by Wall Street Zen reflects ongoing investor concern about efficacy and safety profile.
Red flags
- •24% stock selloff immediately following Q2 2026 earnings and STRO-004 Phase 1 update
- •Dose-limiting toxicities reported at highest dose of lead candidate STRO-004
- •Downgrade to 'strong sell' by Wall Street Zen on September 19, 2026
- •Limited efficacy details disclosed; next clinical update delayed until 2027
- •Significant disconnect between analyst views (Wedbush $60 target vs. Wall Street Zen 'strong sell')
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).